Professor Patrono’s research has brought clinical benefit to many millions of people worldwide. In this interview with Pennie Taylor, health journalist, he reflects on a distinguished career; aspirin’s long legacy and its promising prospects. Reminding us that platelets are key, because that’s what aspirin does; its job at low doses is to selectively acetylate that single amino acid, of that single platelet protein, due to that simple chemical modification that Felix Hoffmann introduced 125 years ago.
Professor Patrono discusses the role of platelets and aspirin’s therapeutic role past, present and future. He also speaks about his pride in having been able to convince clinical investigators in the cardiology and neurology field to initiate clinical trials to test the efficacy and safety of low dose aspirin.
Prof Patrono gave a State-of-the-Art lecture at the International Society on Thrombosis and Haemostasis (ISTH) congress 2021. Click here to access this key paper.